Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Oktober 2019 07:00 ET | Quelle: Neovasc, Inc.

Neovasc Reducer™ for Treatment of Refractory Angina Featured in Sponsored Session at the 40th Annual National Congress of the Italian Society of Interventional Cardiology

VANCOUVER and MILAN, Oct. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive...
16. Oktober 2019 07:00 ET | Quelle: Neovasc, Inc.

Neovasc Retains Westwicke, ICR for Integrated Communications Counsel

Company Ramps Up Commercialization of Neovasc Reducer™ and Development of Tiara™ Product Platforms, Primes for Pivotal Growth Period VANCOUVER, Oct. 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --...
15. Oktober 2019 07:00 ET | Quelle: Neovasc, Inc.

Neovasc Announces Notice of US Patent Granted for Tiara™ Transcatheter Device for Treatment of Severe Mitral Regurgitation

VANCOUVER, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter...
03. September 2019 08:55 ET | Quelle: Neovasc, Inc.

The European Society of Cardiology Includes Neovasc Reducer™ for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes

VANCOUVER, British Columbia, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral...

Vorherige Seite